Male face anatomy in the focus of aesthetic medicine

Bibliography:
1. Scherer M. Specific aspects of a combined approach to male face correction: botulinum toxin A and volumetric fillers. Journal of Cosmetic Dermatology 2016; 1: 1-9.
2. American Society for Plastic Surgery: 2011 statistics. Available from: http://www.plasticsurgery.org/News-and-Resources/2011-Statistics-.html (November 5, 2012)
3. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840-9
4. Yutskovskaya Y, Taran M. Gender peculiarities of botulinum toxin therapy in men. Cosmetic international 2013; 4: 38-43
5. Roginskiy YY, Levin MG. The basics of anthropology. The 3-d edition. Moscow: Vysschaya schkola, 1978; 528 p.
6. Janssen I, Hemsfield S, Wang Z, et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 years. JAppI Physiol 2000; 89: 81-8
7. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg 2008; 32: 724-30
8. Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol 2009; 48: 768-76
9. Keaney T, Alster T. Botulinum Toxin in Men: Review of Relevant Anatomy and Clinical Trial Data Dermatol Surg 2013; 39: 1434-43
10. Golubev VL. The man's face from the point of view of its attractiveness (on materials of the lectures for cosmetologists). Vestnikesteticheskoj meditsiny 2014; 13 (2): 51-55
11. Moretti G, Ellis RA, Mescon H. Vascular patterns in the skin ofthe face. J Invest Dermatol 1959; 33: 103-12
12. Mayrovitz HN, Regan MB. Gender differences in facial skin blood perfusion during basal and heated conditions determined by laser Doppler flowmetry. Microvasc Res 1993; 45: 211-8
13. Montagna W, Ellis RA. Histology and cytochemistry of human skin. XIII: The blood supply ofthe hair follicle. J Nail Cancer Inst 1957; 19:451-63
14. De Maio M. Ethnic and Gender Considerations in the Use of Facial Injectables: Male Patients. Plast Reconstr Surg 2015; 136:40
15. De Maio M, Rzany B. Facial aesthetics in male patients. In: The Male Patient in Aesthetic Medicine. Berlin: Heidelberg; Springer-Verlag, 2009; p. 1-18
16. Paes EC, Teepen HJ, Koop WA, et al. Perioral wrinkles: histologic differences between men and women. Aesthet Surg J 2009; 29: 467-72
17. Ezure T, Yagi E, Kunizawa N, et al. Comparison of sagging at the cheek and lower eyelid between male and female faces. Skin ResTechnol 2011; 17: 510-5
18. Sjostrom L, Smith U, Krotkiewski M, et al. Cellularity in different regions of adipose tissue in young men and women. Metabolism 1972; 21: 1143-53
19. Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placeboin patients with crow's feet. J Am Acad Dermatol 2002; 47: 834-40
20. Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257-62
21. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223-33
22. Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320-6
23. Monheit G, Carruthers A, Brandt F. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33 (1 Spec No.): S51-9
24. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35: 1478-86
25. Brandt F, Swanson N, Baumann L, et al. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009; 35: 1893-901
26. Kane MAC, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new US botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124: 1619-29
27. Rubin MG, Dover JS, Glogau RG, et al. The efficacy and safety of a new U. S. botulinum toxin type A in there treatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009; 8: 439-44
28. Moy R, Maas C, Monheit G, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009; 11: 77-83
29. Imhof M, Kuhne U. A phase III study of incobotulinum toxin A in the treatment of glabellar frown lines. J Clin Aesthet Dermatol 2011; 4: 28-34.